Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BioCardia, Inc. (BCDA)

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society Meeting

Neutral Impact 2 of 5 product/contract Written later

BioCardia announced that it will present a scientific poster on the design of its CardiAMP HF II trial at the Heart Failure Society of America Annual Scientific Meeting in Phoenix, Arizona, October 9 to 12, 2026. The filing says FDA recently agreed that the ongoing trial may be sufficient to support FDA approval, but it contains no financial results, and the event is a scientific presentation rather than a financial or regulatory decision.

Key points

  • Poster presentation at HFSA Annual Scientific Meeting in Phoenix, Arizona, October 9 to 12, 2026
  • Presentation covers the design and scientific support for the CardiAMP HF II Study in ischemic heart failure with reduced ejection fraction
  • FDA recently agreed that the ongoing CardiAMP HF II trial may be sufficient to support FDA approval
  • The filing reports no revenue, earnings or guidance figures

The filing

CompanyBioCardia, Inc. (BCDA)
Form8-K, current report
Filed with the SECOct 7, 2026, 9:00 AM ET
Accession number0001437749-26-032270

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.